Wordt geladen...
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
BACKGROUND: Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab....
Bewaard in:
| Hoofdauteurs: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2011
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3268553/ https://ncbi.nlm.nih.gov/pubmed/21991949 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa0910383 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|